Pregnancy SmartShop formulas

Symptom guide · Pregnancy Smart

Starting medication for opioid use disorder in pregnancy

Assigned clinical reviewerPerry Friedman· MD, FACOG-MFMDraft · pending clinical reviewUpdated

By trimester

Weeks 1–13

1st trimester

Starting early, even in the first trimester, is linked to easier ongoing engagement with prenatal care overall, and the induction process itself is not tied to one specific trimester: what matters clinically is confirming opioid dependence and beginning under monitored, symptom-guided dosing whenever the decision is made.

Weeks 14–27

2nd trimester

If the decision comes in the second trimester, the same short, monitored hospital stay applies, and this is a reasonable point to ask directly how the practice documents your case, since fear of that documentation triggering an unwanted child-welfare report is a well-recognized reason people delay this conversation.

Weeks 28–birth

3rd trimester

Starting in the third trimester still connects directly to what happens right after birth: ask specifically how the nursery team plans to watch for and support a newborn who may show withdrawal signs in the first days of life, since parental involvement at that point is described as an important part of that care.

What does the evidence show for starting medication for opioid use disorder?

  • In a study of inpatient buprenorphine induction, the median hospital stay was about 3 days (range 2 to 12), with the starting dose set relative to a standardized withdrawal-scale score, and mild to moderate withdrawal symptoms confirmed before the first dose, since buprenorphine's own mechanism can trigger a worse reaction if given too early. 1
  • In that same study, patients started at a higher initial dose (8 mg) had shorter hospital stays and needed fewer dose adjustments than those started lower (2 to 4 mg); the median dose at discharge was about 10 mg (range 4 to 20), and most patients who followed up afterward needed no further dose changes and had good outcomes. 1
  • Fear of child-welfare or custody involvement is described in qualitative research as directly counterproductive to recovery: participants reported that the ongoing worry of child removal itself triggered a return to opioid use, creating a cycle in which the fear undermines the stability that starting medication is meant to support. 2
  • That same research found that overlapping stigma from both the healthcare system and the child-welfare system led pregnant and parenting people with opioid use disorder to avoid care and recovery-support services altogether, not merely delay reaching out. 2
  • The legal fear behind this hesitation is grounded in real policy variation, not just perception: prenatal substance use is classified as child abuse under civil child-welfare statutes in 23 states and the District of Columbia, and 25 states plus the District of Columbia require health-care professionals to report suspected prenatal drug use. 3
  • Provider-side bias has also been documented directly: one cited survey found 75% of primary care physicians said they would be unwilling to have someone with opioid use disorder marry into their family, and 66% labeled people with opioid use disorder as dangerous; a separate study found pregnant callers with state-funded insurance were less likely to secure an appointment for medication for opioid use disorder than other callers. 3
  • Neonatal opioid withdrawal, the current term for what was called neonatal abstinence syndrome, is defined as occurring within the first 28 days of life, and CDC guidance describes care that involves and supports the mother specifically as very important once signs appear, underscoring that starting medication does not sideline a parent from their newborn's care. 4

What the induction process commonly looks like

StepWhat the reviewed research found
Before the first doseMild to moderate withdrawal symptoms are confirmed first, since starting too early can trigger a worse reaction
Starting doseSet using a standardized withdrawal-scale score; commonly 4 to 8 mg to start
Hospital stayA median of about 3 days (range 2 to 12 days) in the reviewed cohort
Discharge doseA median of about 10 mg (range 4 to 20 mg), individualized from there
After dischargeMost people needed no further dose changes and had good outcomes at follow-up

When should I call my provider about starting medication for opioid use disorder?

Opioid withdrawal during pregnancy that isn't medically supported is itself a medical urgency, which is part of why induction is monitored rather than managed alone: buprenorphine started before withdrawal is established can trigger a worse reaction. After birth, a newborn with excessive irritability, feeding difficulty, or other withdrawal signs, which can appear within the first 28 days of life, needs the care team told right away rather than waiting to see if symptoms settle on their own. When in doubt, call your obstetric team the same day. Early input almost always beats waiting, and the on-call line exists exactly for this.

Frequently asked questions

What actually happens in the hospital when you start buprenorphine while pregnant?

In the research reviewed here, the typical stay was about 3 days, with the starting dose set using a standardized withdrawal-scale score. Mild to moderate withdrawal symptoms are confirmed before the first dose is given, since starting too early can make things worse rather than better.

Why do you have to already be in some withdrawal before getting the first dose?

Because of how buprenorphine works in the body, giving it before withdrawal is established can trigger a stronger reaction than waiting would. That's a dosing-safety step built into the induction process, not a punitive delay.

Does starting on a higher initial dose mean a rougher process?

In the data reviewed here, the opposite was true: people started at a higher initial dose had shorter hospital stays and needed fewer dose changes than those started on a lower dose.

Will starting medication for opioid use disorder mean my baby is automatically reported to child welfare?

Not automatically, but the fear is grounded in real policy, not just perception. Reporting requirements and how prenatal substance use is classified legally vary by state, and research has found that even medically supported use of these medications during pregnancy can still sometimes lead to inappropriate child-welfare referrals. Ask your specific practice how this is handled in your state.

Is fear of losing custody actually a common reason people avoid starting, or is that overstated?

It's documented as a real and significant barrier, not an overstated one. Research describes the ongoing worry of child removal as something that itself triggered a return to opioid use for some participants, a cycle researchers call counterproductive to the stability that recovery depends on.

Will my doctor judge me for needing this?

Some providers do carry documented bias: one survey found 75% of primary care physicians said they would be unwilling to have someone with opioid use disorder marry into their family, and that kind of bias has been shown to affect appointment access for pregnant callers. Naming this isn't meant to discourage you, it's to validate that any wariness you feel isn't baseless, and to encourage seeking out a provider or program experienced in this specific care.

What happens with my baby right after birth if I'm on this medication?

Withdrawal signs in a newborn, assessed within the first 28 days of life, are managed with care that specifically involves and supports the parent, and generally only babies with more noticeable signs need medication of their own for symptoms.

Does starting medication mean I did something wrong, or is it the recommended step?

It's described as the recommended, supportive step rather than a mark against you. Medically supported opioid maintenance during pregnancy is associated with better ongoing engagement in prenatal care, which is the opposite of a red flag on your chart.

References

  1. Inpatient Buprenorphine Induction for Opioid Use Disorder in Pregnancy

    PMC · https://pmc.ncbi.nlm.nih.gov/articles/PMC10113565/

  2. Stigmatization of Pregnant Individuals with Opioid Use Disorder

    PMC · https://pmc.ncbi.nlm.nih.gov/articles/PMC8896218/

  3. Substance Use in Pregnancy: Identifying Stigma and Improving Care

    PMC · https://pmc.ncbi.nlm.nih.gov/articles/PMC8627324/

  4. Treat and Manage Infants Affected by Prenatal Opioid Exposure

    CDC · https://www.cdc.gov/opioid-use-during-pregnancy/treatment/infants-opioid.html

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.